Published in Proc Natl Acad Sci U S A on April 28, 1998
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A (1998) 6.98
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1998) 4.18
Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol (2000) 3.23
PTEN function: how normal cells control it and tumour cells lose it. Biochem J (2004) 3.06
Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol (1999) 2.79
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer (2007) 2.65
Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A (2000) 2.65
Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci U S A (2001) 2.50
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer (2010) 2.45
Pten, a protean tumor suppressor. Am J Pathol (2001) 2.42
PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res (2011) 2.35
The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther (2006) 2.24
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol (2000) 2.23
Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. J Cell Biol (1999) 2.21
Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A (2007) 2.11
Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol (2000) 2.05
Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. J Clin Invest (2012) 2.03
STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A (1999) 1.96
JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A (2012) 1.88
Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci U S A (2001) 1.82
Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol (2001) 1.82
Repression of PTEN phosphatase by Snail1 transcriptional factor during gamma radiation-induced apoptosis. Mol Cell Biol (2008) 1.68
An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate. Prostate (2011) 1.68
Is PTEN loss associated with clinical outcome measures in human prostate cancer? Br J Cancer (2008) 1.66
TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia (2002) 1.61
Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev (2008) 1.61
Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res (2006) 1.60
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet (2002) 1.57
Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol (2007) 1.53
Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol (2003) 1.50
Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal (2009) 1.47
X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization. J Biol Chem (2009) 1.44
Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci Signal (2009) 1.39
PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle (2009) 1.38
Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol (1999) 1.36
Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. Cell Rep (2014) 1.29
Is EGR1 a potential target for prostate cancer therapy? Future Oncol (2009) 1.29
PTEN is destabilized by phosphorylation on Thr366. Biochem J (2007) 1.28
The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma. J Cancer Res Clin Oncol (2003) 1.27
Somatic mutation of PTEN in bladder carcinoma. Br J Cancer (1999) 1.24
Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res (2008) 1.23
PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. Clin Cancer Res (2008) 1.21
miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem (2009) 1.19
Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet (2001) 1.17
Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer (2010) 1.16
Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br J Cancer (2002) 1.16
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer (2010) 1.14
Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies. Mol Med (2011) 1.13
Understanding signaling cascades in melanoma. Photochem Photobiol (2007) 1.10
Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. J Clin Invest (2010) 1.09
Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1. PLoS One (2013) 1.09
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res (2010) 1.09
The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness. J Cell Biol (2001) 1.08
Genomic Rearrangements of PTEN in Prostate Cancer. Front Oncol (2013) 1.07
Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro-inflammatory cytokines/chemokines. EMBO Mol Med (2012) 1.06
Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells. Neoplasia (2007) 1.04
Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med (2008) 1.03
ATP modulates PTEN subcellular localization in multiple cancer cell lines. Hum Mol Genet (2008) 1.03
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol (2008) 1.03
Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas. Virchows Arch (2003) 1.03
Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res (2011) 1.02
Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer. PLoS One (2013) 1.01
Detection of functional PTEN lipid phosphatase protein and enzyme activity in squamous cell carcinomas of the head and neck, despite loss of heterozygosity at this locus. Br J Cancer (2001) 1.01
Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. J Clin Invest (2013) 0.99
Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells. Mol Cancer Res (2010) 0.98
A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1. Am J Pathol (2009) 0.98
PTEN inhibits BMI1 function independently of its phosphatase activity. Mol Cancer (2009) 0.97
Role of IGF-1/IGF-1R in regulation of invasion in DU145 prostate cancer cells. Cancer Cell Int (2008) 0.96
PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am J Pathol (2009) 0.96
Epigenetic regulation of RTK signaling. J Mol Med (Berl) (2017) 0.96
Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer--factors affecting diagnostic success. Radiology (2013) 0.95
Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study. Carcinogenesis (2008) 0.95
Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets (2014) 0.93
Sprouty genes function in suppression of prostate tumorigenesis. Proc Natl Acad Sci U S A (2012) 0.93
Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions. World J Gastroenterol (2005) 0.92
Pten regulates spindle pole movement through Dlg1-mediated recruitment of Eg5 to centrosomes. Nat Cell Biol (2016) 0.92
E17K substitution in AKT1 in prostate cancer. Br J Cancer (2010) 0.91
miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PLoS One (2014) 0.91
Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. PLoS One (2012) 0.90
Prostate cancer ETS rearrangements switch a cell migration gene expression program from RAS/ERK to PI3K/AKT regulation. Mol Cancer (2014) 0.90
Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis (2011) 0.90
Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk. Neoplasia (2003) 0.90
PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer. Am J Pathol (2011) 0.89
Hypoxia-induced down-regulation of neprilysin by histone modification in mouse primary cortical and hippocampal neurons. PLoS One (2011) 0.89
mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocr Relat Cancer (2012) 0.89
HIF-1 alpha: a key survival factor for serum-deprived prostate cancer cells. Prostate (2008) 0.88
Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis. Mol Oncol (2014) 0.88
Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer. Cancer Res (2008) 0.88
ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells. Autophagy (2015) 0.87
ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma. Prostate (2013) 0.86
BAD dephosphorylation and decreased expression of MCL-1 induce rapid apoptosis in prostate cancer cells. PLoS One (2013) 0.86
Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Adv Urol (2012) 0.86
SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1. Mol Endocrinol (2014) 0.86
Green tea polyphenols induce p53-dependent and p53-independent apoptosis in prostate cancer cells through two distinct mechanisms. PLoS One (2012) 0.86
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
An STS-based map of the human genome. Science (1995) 17.72
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet (1997) 15.38
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet (1997) 10.71
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 9.79
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res (1997) 5.92
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A (1997) 5.32
Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med (1997) 5.10
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res (1997) 4.32
Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res (1995) 4.28
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet (1995) 3.76
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med (1997) 3.46
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res (1997) 2.98
PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet (1997) 2.44
Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science (1994) 2.16
Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res (1996) 1.98
Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer (1997) 1.42
Alterations in fascin-expressing germinal center dendritic cells in neoplastic follicles of B-cell lymphomas. Mod Pathol (1998) 0.98
Simultaneous amplification of four DNA repair genes and beta-actin in human lymphocytes by multiplex reverse transcriptase-PCR. Cancer Res (1995) 0.97
Preclinical models of prostate cancer. Semin Oncol (1996) 0.90
The transcriptional landscape of the mammalian genome. Science (2005) 37.63
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
CHARMM: the biomolecular simulation program. J Comput Chem (2009) 27.71
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Functional annotation of a full-length mouse cDNA collection. Nature (2001) 23.61
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med (1995) 21.16
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
An STS-based map of the human genome. Science (1995) 17.72
Antisense transcription in the mammalian transcriptome. Science (2005) 15.69
A gene map of the human genome. Science (1996) 14.32
Lac repressor-operator interaction. I. Equilibrium studies. J Mol Biol (1970) 13.32
A physical map of 30,000 human genes. Science (1998) 12.43
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res (1999) 10.65
Structural parts involved in activation and inactivation of the sodium channel. Nature (1989) 8.72
Existence of distinct sodium channel messenger RNAs in rat brain. Nature (1986) 7.87
New topoisomerase essential for chromosome segregation in E. coli. Cell (1990) 7.19
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
On the process of cellular division in Escherichia coli: a series of mutants of E. coli altered in the penicillin-binding proteins. Proc Natl Acad Sci U S A (1978) 6.93
Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. Science (1997) 6.75
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res (1995) 5.11
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res (2001) 5.11
Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells. Nature (1997) 5.08
Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (1996) 5.06
Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature (1994) 5.00
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res (1999) 4.67
On the process of cellular division in Escherichia coli: a mutant of E. coli lacking a murein-lipoprotein. Proc Natl Acad Sci U S A (1977) 4.58
A cytoplasmic inhibitor of the JNK signal transduction pathway. Science (1997) 4.56
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res (2001) 4.51
Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet (1995) 4.45
Mutants of Escherichia coli lacking in highly penicillin-sensitive D-alanine carboxypeptidase activity. Proc Natl Acad Sci U S A (1977) 4.44
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev (1994) 4.30
Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol (2001) 4.22
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 4.20
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1998) 4.18
Chalcones: an update on cytotoxic and chemoprotective properties. Curr Med Chem (2005) 3.97
Hereditary prostate cancer: epidemiologic and clinical features. J Urol (1993) 3.86
Array-based genomic resequencing of human leukemia. Oncogene (2010) 3.77
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol (1988) 3.66
Loss of function of a rice brassinosteroid insensitive1 homolog prevents internode elongation and bending of the lamina joint. Plant Cell (2000) 3.56
Gene fliA encodes an alternative sigma factor specific for flagellar operons in Salmonella typhimurium. Mol Gen Genet (1990) 3.49
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med (1997) 3.46
Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A (1998) 3.46
On the process of cellular division in Escherichia coli: nucleotide sequence of the gene for penicillin-binding protein 3. Mol Gen Genet (1983) 3.43
The highly reduced genome of an enslaved algal nucleus. Nature (2001) 3.31
A novel transcriptional regulation mechanism in the flagellar regulon of Salmonella typhimurium: an antisigma factor inhibits the activity of the flagellum-specific sigma factor, sigma F. Mol Microbiol (1992) 3.31
Primary structure of the alpha-subunit of transducin and its relationship to ras proteins. Nature (1985) 3.28
The membrane properties of the smooth muscle cells of the rabbit main pulmonary artery. J Physiol (1977) 3.24
Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A (1994) 3.24
Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci U S A (1997) 3.22
A high-throughput SNP typing system for genome-wide association studies. J Hum Genet (2001) 3.18
DNA structure-dependent requirements for yeast RAD genes in gene conversion. Nature (1995) 3.15
Chemical etiology of nucleic acid structure: the alpha-threofuranosyl-(3'-->2') oligonucleotide system. Science (2000) 3.11
Excitation-contraction coupling in the smooth muscle cells of the rabbit main pulmonary artery. J Physiol (1977) 3.06
Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol (1997) 3.02
Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia (2003) 3.00
Expression of functional sodium channels from cloned cDNA. Nature (1986) 2.95
NEDD8 recruits E2-ubiquitin to SCF E3 ligase. EMBO J (2001) 2.94
Excitation--contraction coupling in smooth muscle cells of the guinea-pig mesenteric artery. J Physiol (1981) 2.92
Murein-lipoprotein of Escherichia coli: a protein involved in the stabilization of bacterial cell envelope. Mol Gen Genet (1978) 2.84
Longitudinal pattern of regional brain volume change differentiates normal aging from MCI. Neurology (2009) 2.84
Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet (1999) 2.81
Excess amantadine use and resistant viruses. Lancet (2001) 2.81
Hepatitis B e antigen and infectivity of hepatitis B virus. J Infect Dis (1977) 2.80
mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol (1996) 2.78
Fluorescence resonance energy transfer from cyan to yellow fluorescent protein detected by acceptor photobleaching using confocal microscopy and a single laser. J Microsc (2003) 2.74
Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer (2012) 2.74
Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA (1997) 2.73
A single point mutation confers tetrodotoxin and saxitoxin insensitivity on the sodium channel II. FEBS Lett (1989) 2.73
Processing of the notch ligand delta by the metalloprotease Kuzbanian. Science (1999) 2.71
Role for the class A macrophage scavenger receptor in the phagocytosis of apoptotic thymocytes in vitro. Proc Natl Acad Sci U S A (1996) 2.69
Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst (1999) 2.68
Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res (1998) 2.67
Innervation and properties of the smooth muscle of the dog trachea. Jpn J Physiol (1976) 2.65
Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A (2000) 2.65
Factors modifying contraction-relaxation cycle in vascular smooth muscles. Am J Physiol (1982) 2.63
Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res (1999) 2.62
Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene (2000) 2.61
Sequestration and inhibition of Daxx-mediated transcriptional repression by PML. Mol Cell Biol (2000) 2.59
Different forms of TFIIH for transcription and DNA repair: holo-TFIIH and a nucleotide excision repairosome. Cell (1995) 2.58
Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res (1992) 2.55
The role of cAMP in flagellation of Salmonella typhimurium. Mol Gen Genet (1976) 2.54
Past adult lead exposure is linked to neurodegeneration measured by brain MRI. Neurology (2006) 2.52
Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res (2001) 2.50
Purification and characterization of DNA topoisomerase IV in Escherichia coli. J Biol Chem (1992) 2.50
CIDE, a novel family of cell death activators with homology to the 45 kDa subunit of the DNA fragmentation factor. EMBO J (1998) 2.44
Ampulla cardiomyopathy ('Takotusbo' cardiomyopathy)--reversible left ventricular dysfunction: with ST segment elevation. Jpn Circ J (2000) 2.39
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res (1999) 2.38